ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor against Respiratory Syncytial Virus Oct 31, 2016 by ReViral Ltd Read More
ReViral Announces US$21 million Fundraising to Advance Clinical Development of a Novel Antiviral Drug Sep 8, 2015 by ReViral Ltd Read More
ReViral has been granted a Seeding Drug Discovery award from the Wellcome Trust to develop novel small molecule RSV fusion inhibitors Dec 6, 2013 by ReViral Ltd Read More
